Dupilumab Efficacy and Safety in Adolescents with Moderate-to-Severe Atopic Dermatitis: A Case Series.
作者信息
Mareschal Adrien, Puzenat Eve, Aubin François
机构信息
Department of Dermatology, University Hospital, Besançon, France.
出版信息
Acta Derm Venereol. 2020 Jan 7;100(1):adv00014. doi: 10.2340/00015555-3368.
Abstract
摘要
相似文献
1
Dupilumab Efficacy and Safety in Adolescents with Moderate-to-Severe Atopic Dermatitis: A Case Series.度普利尤单抗治疗中度至重度特应性皮炎青少年的疗效与安全性：病例系列
Acta Derm Venereol. 2020 Jan 7;100(1):adv00014. doi: 10.2340/00015555-3368.
2
Safety of dupilumab in patients with atopic dermatitis: expert opinion.治疗特应性皮炎患者的度普利尤单抗的安全性：专家意见。
Expert Opin Drug Saf. 2021 Sep;20(9):997-1004. doi: 10.1080/14740338.2021.1939673. Epub 2021 Jun 19.
3
Remittive effect of Dupilumab in atopic dermatitis.度普利尤单抗在特应性皮炎中的缓解作用。
Dermatol Ther. 2018 Nov;31(6):e12711. doi: 10.1111/dth.12711. Epub 2018 Sep 25.
4
Dupilumab Versus Cyclosporine for the Treatment of Moderate-to-Severe Atopic Dermatitis in Adults: Indirect Comparison Using the Eczema Area and Severity Index.度普利尤单抗与环孢素治疗成人中重度特应性皮炎：基于湿疹面积及严重程度指数的间接比较
Acta Derm Venereol. 2019 Sep 1;99(10):851-857. doi: 10.2340/00015555-3219.
5
Efficacy and Safety of Multiple Dupilumab Dose Regimens After Initial Successful Treatment in Patients With Atopic Dermatitis: A Randomized Clinical Trial.多种度普利尤单抗剂量方案在特应性皮炎初始成功治疗后的疗效和安全性：一项随机临床试验。
JAMA Dermatol. 2020 Feb 1;156(2):131-143. doi: 10.1001/jamadermatol.2019.3617.
6
Dupilumab for atopic dermatitis: evidence to date.度普利尤单抗治疗特应性皮炎：现有证据。
G Ital Dermatol Venereol. 2019 Dec;154(6):696-713. doi: 10.23736/S0392-0488.19.06417-4. Epub 2019 Jun 17.
7
The use of selective Th2 blocker dupilumab for the treatment of atopic dermatitis in a heart transplant patient: Case report.在心脏移植患者中使用选择性 Th2 阻滞剂度普利尤单抗治疗特应性皮炎：病例报告。
Dermatol Ther. 2019 Nov;32(6):e13144. doi: 10.1111/dth.13144. Epub 2019 Nov 11.
8
Dupilumab in atopic dermatitis, a protocol for SARS-COV-2-infected patients.度普利尤单抗治疗特应性皮炎：SARS-CoV-2感染患者的方案
Dermatol Ther. 2020 Nov;33(6):e14172. doi: 10.1111/dth.14172. Epub 2020 Sep 5.
9
Real-world outcomes of children treated with dupilumab for moderate-to-severe atopic dermatitis: a single-centre retrospective observational UK study.真实世界中接受度普利单抗治疗中重度特应性皮炎儿童的结局：一项英国单中心回顾性观察研究。
Clin Exp Dermatol. 2024 May 21;49(6):578-583. doi: 10.1093/ced/llae013.
10
Occurrence of psoriasiform eruption during dupilumab therapy for adult atopic dermatitis: A case series.度普利尤单抗治疗成人特应性皮炎期间银屑病样皮疹的发生：病例系列
Dermatol Ther. 2019 Nov;32(6):e13142. doi: 10.1111/dth.13142. Epub 2019 Nov 21.
引用本文的文献
1
Moderate-to-severe atopic dermatitis in adolescents treated with dupilumab: A multicentre Italian real-world experience.青少年中重度特应性皮炎患者接受度普利尤单抗治疗的多中心意大利真实世界经验。
J Eur Acad Dermatol Venereol. 2022 Aug;36(8):1292-1299. doi: 10.1111/jdv.18141. Epub 2022 Apr 22.
2
Dupilumab induces a rapid decrease of pruritus in adolescents: A pilot real-life study.度普利尤单抗可使青少年瘙痒迅速减轻：一项真实世界的初步研究。
Dermatol Ther. 2021 Nov;34(6):e15115. doi: 10.1111/dth.15115. Epub 2021 Sep 2.
3
Dupilumab in adolescents with moderate to severe atopic dermatitis: a 32-week real-world experience during the COVID-19 pandemic.度普利尤单抗治疗中度至重度特应性皮炎青少年患者：COVID-19大流行期间的32周真实世界经验
Clin Exp Dermatol. 2022 Jan;47(1):165-167. doi: 10.1111/ced.14862. Epub 2021 Aug 24.
4
Dupilumab for the Treatment of Atopic Dermatitis in an Austrian Cohort-Real-Life Data Shows Rosacea-Like Folliculitis.度普利尤单抗治疗奥地利队列特应性皮炎——真实数据显示酒渣鼻样毛囊炎
J Clin Med. 2020 Apr 24;9(4):1241. doi: 10.3390/jcm9041241.
本文引用的文献
1
Dupilumab in adolescents with uncontrolled moderate-to-severe atopic dermatitis: results from a phase IIa open-label trial and subsequent phase III open-label extension.度普利尤单抗治疗青少年中未得到控制的中重度特应性皮炎：一项 IIa 期开放标签试验及后续 III 期开放标签扩展研究的结果。
Br J Dermatol. 2020 Jan;182(1):85-96. doi: 10.1111/bjd.18476. Epub 2019 Oct 8.
2
Infections in Dupilumab Clinical Trials in Atopic Dermatitis: A Comprehensive Pooled Analysis.特应性皮炎度普利尤单抗临床试验中的感染：综合汇总分析。
Am J Clin Dermatol. 2019 Jun;20(3):443-456. doi: 10.1007/s40257-019-00445-7.
3
Conjunctivitis in atopic dermatitis patients with and without dupilumab therapy - international eczema council survey and opinion.特应性皮炎患者在接受和未接受度普利尤单抗治疗时的结膜炎情况——国际特应性皮炎理事会的调查和意见。
J Eur Acad Dermatol Venereol. 2019 Jul;33(7):1224-1231. doi: 10.1111/jdv.15608. Epub 2019 May 6.
4
Conjunctivitis in dupilumab clinical trials.临床试验中的结膜炎。
Br J Dermatol. 2019 Sep;181(3):459-473. doi: 10.1111/bjd.17869. Epub 2019 May 7.
5
Effectiveness and safety of dupilumab for the treatment of atopic dermatitis in a real-life French multicenter adult cohort.度普利尤单抗治疗真实世界中法国多中心成人队列特应性皮炎的疗效和安全性。
J Am Acad Dermatol. 2019 Jul;81(1):143-151. doi: 10.1016/j.jaad.2019.02.053. Epub 2019 Feb 27.
6
Use of dupilumab in pediatric atopic dermatitis: Access, dosing, and implications for managing severe atopic dermatitis.度普利尤单抗在儿童特应性皮炎中的应用：可及性、给药方案及对重度特应性皮炎管理的意义
Pediatr Dermatol. 2019 Jan;36(1):172-176. doi: 10.1111/pde.13707.
7
Long-term off-label dupilumab in pediatric atopic dermatitis: A case series.儿童特应性皮炎长期使用度普利尤单抗的超说明书用药：病例系列
Pediatr Dermatol. 2019 Jan;36(1):85-88. doi: 10.1111/pde.13697. Epub 2018 Oct 18.
8
Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial.度普利尤单抗联合外用皮质类固醇治疗中重度特应性皮炎的长期管理（LIBERTY AD CHRONOS）：一项为期 1 年、随机、双盲、安慰剂对照、3 期临床试验。
Lancet. 2017 Jun 10;389(10086):2287-2303. doi: 10.1016/S0140-6736(17)31191-1. Epub 2017 May 4.
9
Two Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis.两项度普利尤单抗治疗特应性皮炎的 3 期临床试验。
N Engl J Med. 2016 Dec 15;375(24):2335-2348. doi: 10.1056/NEJMoa1610020. Epub 2016 Sep 30.
10
Targeting key proximal drivers of type 2 inflammation in disease.针对 2 型炎症疾病的关键近端驱动因素。
Nat Rev Drug Discov. 2016 Jan;15(1):35-50. doi: 10.1038/nrd4624. Epub 2015 Oct 16.
Zotero 插件